PTC Therapeutics pays ~$225M upfront to cancel Censa sepiapterin royalty obligations

PTC THERAPEUTICS, INC.

Upfront cash payment of ~$225M to former Censa securityholders eliminates 8-12% annual net sales royalties.
Original milestones: 8% on sales ≤$250M, 10% on $250M-$500M, 12% on >$500M.
Additional Milestone Payments up to $100M each (total $500M) based on cumulative net sales thresholds (e.g., $3B, $5B, $7B, $9B, $11B).
Participation was ~90% of former Censa securityholders; remaining may join and receive pro rata consideration.
Sepiapterin is the product; other merger obligations remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.